Typing method

• US 11,535,893 B2
• Filed: 06/19/2019
• Issued: 12/27/2022
• Est. Priority Date: 12/23/2016
• Status: Active Grant

• Current Assignee: Oxford BioDynamics, PLC
• Original Assignee: Oxford BioDynamics, PLC
• Inventors: Ramadass, Aroul Selvam, Hunter, Ewan, Akoulitchev, Alexandre
• Primary Examiner(s): Haney, Amanda
• Application Number:
  US16/446,255
• Publication Number:
  US 20190309367A1
• Time in Patent Office: 1,287 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2523/101 Crosslinking agents, e.g. psoralen
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development

Abstract

The invention provides a method of determining the epigenetic chromosome interactions which are relevant to an epigenetic test for a neurodegenerative condition.

Claims

1. A method of identifying a human individual in need of therapy for Alzheimer'"'"'s disease and treating the identified human individual, the method comprising:

(A) assaying a blood sample from a human individual for ten chromosome interactions, wherein said assaying comprises the steps of;

(a) performing in vitro cross-linking of chromosome regions of the human individual which have come together in a chromosome interaction to form cross- linked nucleic acid;

(b) subjecting said cross-linked nucleic acid to restriction digestion cleavage with an enzyme to form cross-linked cleaved nucleic acids;

(c) ligating said cross-linked cleaved nucleic acid ends to form a ligated nucleic acid; and

(d) detecting the ligated nucleic acid to determine the presence or absence of a chromosome interaction and wherein the ten chromosome interactions are the following chromosomal interactions;

(i) the chromosome interaction on chromosome 12 that results in a ligated nucleic acid comprising SEQ ID NO;

8;

(ii) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO;

1;

(iii) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO;

19;

(iv) the chromosome interaction on chromosome 3 that results in a ligated nucleic acid comprising SEQ ID NO;

5;

(v) the chromosome interaction on chromosome 8 that results in a ligated nucleic acid comprising SEQ ID NO;

2;

(vi) the chromosome interaction on chromosome 10 that results in a ligated nucleic acid comprising SEQ ID NO;

24;

(vii) the chromosome interaction on chromosome 9 that results in a ligated nucleic acid comprising SEQ ID NO;

6;

(viii) the chromosome interaction on chromosome 11 that results in a ligated nucleic acid comprising SEQ ID NO;

20;

(ix) the chromosome interaction on chromosome 3 that results in a ligated nucleic acid comprising SEQ ID NO;

21; and

(x) the chromosome interaction on chromosome 7 that results in a ligated nucleic acid comprising SEQ ID NO;

15;

(B) identifying the human individual as being in need of therapy for Alzheimer'"'"'s disease when one or more of chromosome interactions (i)-(vii) are present and/or one or more of chromosome interactions (viii)-(x) are absent; and

(C) administering to the identified human individual an agent that is therapeutic for Alzheimer'"'"'s disease.